The main cause of prostate enlargement is the lifelong exposure of prostate tissue to hormones, particularly a potent form of testosterone called dihydrotestosterone (DHT). Nearly every man will experience some degree of prostate growth if he lives long enough: about 50% of men in their 50s have benign prostatic hyperplasia (BPH), 70% of men in their 60s, and around 80% of men over 70.
But hormones alone don’t tell the full story. Aging shifts the balance between testosterone and estrogen, metabolic conditions like obesity amplify the process, and smooth muscle tension in the prostate compounds the symptoms. Here’s how it all fits together.
How DHT Drives Prostate Growth
Your body converts testosterone into DHT using an enzyme called 5-alpha reductase. DHT is far more potent at stimulating prostate cells than testosterone itself. Once DHT binds to receptors inside prostate cells, it triggers a chain of signals that tell those cells to multiply. Specifically, DHT activates a signaling cascade involving proteins called MAP kinases and a gene activator called c-Jun, which together switch on genes that promote cell growth. This process happens in the stromal cells of the prostate, the connective tissue that makes up much of the gland’s bulk.
In younger men, prostate cell growth and cell death stay roughly in balance. As men age, DHT continues to accumulate in prostate tissue even as overall testosterone levels in the blood decline. The result is a slow, steady expansion of the gland that can eventually squeeze the urethra and interfere with urinary flow. This is why BPH is virtually nonexistent in men under 30 but nearly universal by the eighth decade of life.
The Hormone Shift That Comes With Aging
Testosterone levels drop by roughly 1% to 2% per year as men get older. That might sound like it would protect the prostate, but the picture is more complicated. While testosterone falls, estrogen levels can remain stable or even rise, especially in men who carry excess body fat, since fat tissue converts testosterone into estrogen. This shifting ratio appears to matter: animal studies show that a combination of low testosterone and elevated estrogen promotes prostate inflammation, which itself fuels tissue growth.
Low testosterone may also directly stimulate inflammatory pathways in the prostate. Chronic, low-grade inflammation thickens prostate tissue over time, contributing to both the enlargement and the urinary symptoms that come with it. So the hormonal cause of BPH isn’t simply “too much testosterone.” It’s the changing relationship between multiple hormones over decades.
Why Obesity and Metabolic Health Matter
Metabolic syndrome, the cluster of conditions that includes insulin resistance, obesity, high blood pressure, and abnormal cholesterol, is now recognized as a significant contributor to prostate enlargement. Men with metabolic syndrome tend to develop larger prostates and more severe urinary obstruction than men without it.
The connection runs through several pathways. Excess insulin and insulin-like growth factor 1 (IGF-1) directly stimulate prostate cell proliferation. Obesity increases estrogen production, worsening the hormonal imbalance described above. Fat tissue also releases inflammatory molecules called adipokines, which promote the kind of chronic inflammation that drives prostate growth. In animal models, metabolic syndrome produced a cascade of effects: glucose intolerance, low testosterone, elevated estrogen, and pronounced prostate inflammation, all feeding into each other.
This link means that weight management and metabolic health aren’t just general wellness goals. They can directly influence how quickly and how severely the prostate enlarges.
Symptoms and How Severity Is Measured
A normal prostate is roughly the size of a walnut, around 20 to 25 cubic centimeters (cc) in volume. Mild enlargement falls in the 25 to 30 cc range, moderate enlargement between 31 and 50 cc, and severe enlargement can push past 50 cc, sometimes reaching 90 cc or more.
Prostate size alone doesn’t determine how bothersome your symptoms are, though. A moderately enlarged prostate can cause significant urinary problems in one man and barely noticeable ones in another. That’s because symptoms depend not just on gland size but on how much the tissue presses on the urethra and how tightly the smooth muscle in the prostate contracts.
Doctors typically assess symptom severity using the International Prostate Symptom Score (IPSS), a seven-question survey covering things like how often you wake up at night to urinate, whether your stream feels weak, and how completely your bladder empties. A score of 0 to 7 indicates mild symptoms, 8 to 19 moderate, and 20 to 35 severe. Treatment decisions are usually guided more by this symptom score than by prostate volume alone.
The Two Components of Urinary Symptoms
BPH causes urinary trouble through two distinct mechanisms that often overlap. The first is the physical bulk of the enlarged tissue pressing inward on the urethra, narrowing the channel urine passes through. The second is increased smooth muscle tone in the prostate and bladder neck. Nerve signals cause these muscles to tighten through receptors called alpha-1 adrenoceptors, and in an enlarged prostate, this tightening can significantly restrict flow even beyond what the tissue bulk alone would cause.
This distinction matters because it explains why two different classes of medication exist for BPH, each targeting a different piece of the problem.
How BPH Is Treated
For mild symptoms, lifestyle changes are the usual starting point: limiting fluids before bed, reducing caffeine and alcohol, and using timed voiding (urinating on a schedule rather than waiting for urgency). These adjustments can make a noticeable difference for many men without any medication.
When symptoms are moderate to severe, two main types of medication are available. Alpha-blockers work by relaxing the smooth muscle in the prostate and bladder neck, widening the urethral channel and improving flow. These medications typically provide relief within days to weeks. The American Urological Association lists several options in this class as first-line treatment for bothersome symptoms.
The second class, 5-alpha reductase inhibitors, attacks the root hormonal cause by blocking the conversion of testosterone to DHT. With less DHT stimulating growth, the prostate can actually shrink over time. These medications work more slowly, often taking three to six months to show their full effect, and are recommended for men whose prostate volume exceeds 30 cc or whose PSA level is above 1.5 ng/mL. For men with both BPH and erectile dysfunction, a daily low-dose erectile dysfunction medication (tadalafil) is also an option, as it relaxes smooth muscle in both the prostate and penile blood vessels.
When medications aren’t enough, several procedural options can remove or reduce excess prostate tissue. These range from minimally invasive office procedures to surgical approaches, and the right choice depends on prostate size, symptom severity, and personal priorities around recovery time and side effects.
BPH and Prostate Cancer Are Separate Conditions
One of the most common concerns men have when they learn their prostate is enlarged is whether it means cancer. BPH and prostate cancer are distinct conditions. BPH is not a precursor to cancer, and having an enlarged prostate does not increase your cancer risk. However, both conditions can cause an elevated PSA (prostate-specific antigen) level on a blood test, which can create confusion.
An elevated PSA does not mean someone has cancer. At the same time, some men are diagnosed with prostate cancer despite having a PSA in the normal range. When PSA is elevated, doctors use additional tools, including the rate of PSA change over time, prostate imaging, and sometimes biopsy, to distinguish between the two conditions. The key takeaway is that BPH is extremely common, almost always benign, and highly treatable.